Left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe: Results of the European Heart Rhythm Association survey

Europace

Volumn 15, Issue 1, 2013, Pages 141-143

  Lip, Gregory Y H ^a   Dagres, Nikolaos ^b   Proclemer, Alessandro ^c   Svendsen, Jesper Hastrup ^d   Pison, Laurent ^e   Blomstrom Lundqvist, Carina ^f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d DANISH NATIONAL RESEARCH FOUNDATION   (Denmark)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticoagulation; Atrial fibrillation; Left atrial appendage occlusion; Stroke

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG CONTRAINDICATION; EUROPE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM APPENDAGE OCCLUSION; HEART TAMPONADE; HUMAN; LONG TERM CARE; MEDICAL DEVICE; OCCLUSION; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

ATRIAL APPENDAGE; ATRIAL FIBRILLATION; COMORBIDITY; EUROPE; HEALTH CARE SURVEYS; HUMANS; INCIDENCE; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; RISK FACTORS; SEPTAL OCCLUDER DEVICE; STROKE; TREATMENT OUTCOME;

EID: 84871194078     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eus413     Document Type: Review

References (13)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation .developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413
2. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-49
3. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol 2011;8:602-6
4. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The swedish atrial fibrillation cohort study. Eur Heart J 2012;33:698-704
5. Landmesser U, Holmes DR Jr. Left atrial appendage closure: A percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J 2011
6. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial. Lancet 2009;374:534-42
7. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: Results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011;123:417-24
8. Kaul S, Cigolani E, Shehata M, Diamond GA. How does left atrial appendage occlusion using the watchman device compare to dabigatran for reducing thromboembolic events in patients with nonvalvular atrial fibrillatioñ J Am Coll Cardiol 2010;55:A4.E39 (abstract
9. National-Institute-for-Health-and-Clinical-Excellence. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. Interventional procedure guidance 349. 2010: june 2010. http://www.nice.org.uk/IP2310aoverview (24 November 2012, date last accessed
10. O'Riordan M. Watchman delayed: fDA wants more data on the LAA-closure device before approving. The heart. Org. [clinical conditions . arrhythmia/ep . arrhythmia/ep]; 19 March 2010. http://www.Theheart.Org/article/1060779.Do (24 November 2012, date last accessed
11. Whitlock RP, Healey JS, Connolly SJ. Left atrial appendage occlusion does not eliminate the need for warfarin. Circulation 2009;120:1927-32; discussion 1932
12. Ahrens I, Lip GY, Peter K. What do the re-ly, averroes and rocket-af trials tell us for stroke prevention in atrial fibrillatioñ Thromb Haemost 2011;105:574-8
13. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47